Skip to main content

Table 1 Baseline demographics and clinical characteristics

From: Impact of 6% balanced hydroxyethyl starch following cardiopulmonary bypass on renal function: a retrospective study

Variables Low dose HES
(n = 1239)
Moderate dose HES
(n = 418)
p-value
Age 58.2 ± 13.6 59.4 ± 14.6 < .001
Female gender 503 (40.6) 251 (60.5) .16
Diabetes mellitus 188 (15.9) 66 (15.7) .76
Hypertension 514 (41.5) 163 (39.0) .36
Cerebrovascular accident 65 (5.2) 18 (4.3) .44
Euro score 2.6 ± 4.1 2.8 ± 4.8 .08
LV ejection fraction, % 58.7 ± 10.2 58.8 ± 10.5 .77
Medication
 Angiotensin receptor blockers 410 (33.1) 140 (33.5) .88
 Diuretics 483 (38.9) 177 (42.3) .22
 Insulin 121 (9.7) 35 (8.3) .39
 Statins 404 (32.6) 144 (34.4) .48
Laboratory
 Hemoglobin, g/dL 12.9 ± 1.9 12.5 ± 1.8 < .001
 Creatinine, mg/dL 0.89 (0.75, 1.06) 0.84 (0.69, 1.01) < .001
 Total bilirubin, mg/dL 0.5 (0.4, 0.8) 0.5 (0.4, 0.8) .94
  1. Results are presented as mean ± SD or median (IQR) as appropriate and number (percentage)
  2. HES Hydroxyethyl starch; LV Left ventricle